Lonza Group AG (SWX: LONN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 39.22B |
| Revenue (ttm) | 6.70B |
| Net Income (ttm) | 573.00M |
| Shares Out | 72.23M |
| EPS (ttm) | 7.92 |
| PE Ratio | 68.54 |
| Forward PE | 35.24 |
| Dividend | 4.00 (0.74%) |
| Ex-Dividend Date | May 13, 2024 |
| Volume | 67,598 |
| Open | 535.60 |
| Previous Close | 543.00 |
| Day's Range | 531.60 - 542.40 |
| 52-Week Range | 308.60 - 589.40 |
| Beta | 0.65 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 30, 2025 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substanc... [Read more]
Financial Performance
In 2023, Alcon's revenue was $9.46 billion, an increase of 8.47% compared to the previous year's $8.72 billion. Earnings were $974.00 million, an increase of 190.75%.
Financial StatementsNews
LZAGY, DSDVY: Investment Opportunities Outside of the U.S.
U.S. equity markets have benefitted from a perceived quality advantage over Europe, though it's uncertain when outperformance will end, notes Bryan Lee. He discusses finding investment opportunities o...
Lonza chairman to step down, drugmaker confirms targets, shares soar
Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples ...
Lonza CEO departure prompts concern over earnings prospects
Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about th...
10 Solid Stocks WIth Terrible Tickers
Stocks with long symbols are difficult to remember and easy to overlook. That would be a mistake.
Lonza's first-half core EBITDA gains 16.5%
Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from drugmakers.
Lonza appoints Novartis executive as new Chief Financial Officer
Lonza has appointed former Novartis executive Philippe Deecke as its new Chief Financial Officer, the Swiss chemicals company said on Thursday.
12 European Stocks That Analysts Love and Investors Are Ignoring
The stocks could turn out to be winners in coming months if analysts' upbeat calls turn out to be correct.
aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810
aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical devel...
Lonza shortlists Lanxess, private equity in unit sale, sources say
Swiss contract drug maker Lonza has shortlisted German chemicals group Lanxess and private equity groups in the sale of its Lonza Specialty Ingredients (LSI) unit worth more than 3 billion Swiss franc...